Deletion of GSK-3β in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation

Based on extensive preclinical data, glycogen synthase kinase–3 (GSK-3) has been proposed to be a viable drug target for a wide variety of disease states, ranging from diabetes to bipolar disorder. Since these new drugs, which will be more powerful GSK-3 inhibitors than lithium, may potentially be g...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Kerkela, Risto, Kockeritz, Lisa, MacAulay, Katrina, Zhou, Jibin, Doble, Bradley W., Beahm, Cara, Greytak, Sarah, Woulfe, Kathleen, Trivedi, Chinmay M., Woodgett, James R., Epstein, Jonathan A., Force, Thomas, Huggins, Gordon S.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society for Clinical Investigation 2008
Θέματα:
Research Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2556242/
https://ncbi.nlm.nih.gov/pubmed/18830417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI36245
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια